Literature DB >> 10402300

New self-expanding patent foramen ovale occlusion device.

Y M Han1, X Gu, J L Titus, C Rickers, J L Bass, M Urness, K Amplatz.   

Abstract

Our purpose was to evaluate a new self-expanding device for closure of the patent foramen ovale (PFO). A transeptal catheter passage through the flap of the fossa ovalis was performed with a transeptal needle inside a catheter, creating a PFO in two minipigs. In an additional five animals, a naturally occurring PFO was found. The device is made from 0.005 inch nitinol wire mesh with polyester fabric inside, similar in construction to the Amplatzer atrial septal occluder. However, the left atrial disc is smaller (18 mm) than the right atrial disc (26 mm). Both discs are connected by a very short flexible waist (3 mm) that allows free movement of both retention discs. Pulmonary and right atrial angiography were performed after placement, at 1 month, and at 3 months follow-up. Placement of the device was technically successful in six animals. One animal died from ventricular fibrillation during placement. Pulmonary angiography and echocardiography showed complete occlusion of the PFO in six animals. Two animals were sacrificed after 1 month and four animals after 3 months. In the animals sacrificed at 1 month, histopathological examination showed partial (n = 2) endothelialization, and in the 3 months follow-up group (n = 4) endothelialization was complete. The device appears to be highly effective for occlusion of PFOs. This procedure may be performed as an outpatient procedure due to the small 7 Fr delivery system sheath. Cathet. Cardiovasc. Intervent. 47:370-376, 1999. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10402300     DOI: 10.1002/(sici)1522-726x(199907)47:3<370::aid-ccd27>3.0.co;2-9

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  8 in total

1.  Percutaneous closure of patent foramen ovale: impact of device design on safety and efficacy.

Authors:  M Schwerzmann; S Windecker; A Wahl; H Mehta; K Nedeltchev; H Mattle; C Seiler; B Meier
Journal:  Heart       Date:  2004-02       Impact factor: 5.994

2.  Patent foramen ovale morphology and impact on percutaneous device closure.

Authors:  H G El Said; C J McMahon; C E Mullins; R H Pignatelli; R G Grifka; M R Nihill; J A Vincent
Journal:  Pediatr Cardiol       Date:  2005 Jan-Feb       Impact factor: 1.655

3.  Reoperation after mitral valve repair in viewpoints of kidney injury as well as hemolytic anemia.

Authors:  Ryo Ishida; Takaomi Adachi; Yayoi Shiotsu; Mami Ishida; Yasukiyo Mori; Kiyoshi Doi; Keiichi Tamagaki
Journal:  CEN Case Rep       Date:  2014-10-18

4.  Endocarditis and Incomplete Endothelialization 12 Years after Amplatzer Septal Occluder Deployment.

Authors:  Allan K Nguyen; Brian A Palafox; Joanne P Starr; Richard N Gates; Farbouch Berdjis
Journal:  Tex Heart Inst J       Date:  2016-06-01

5.  Late Bacterial Endocarditis in an Intravenous Drug User With an Amplatzer Septal Occluder.

Authors:  Michael S La Sala; Hajir Zohourian; Joseph McKeown; Samuel Snyder
Journal:  Tex Heart Inst J       Date:  2020-08-01

6.  Incomplete endothelialization of an intravascular implant and fatal late-onset bacterial ductal arteritis in a dog with occluded patent ductus arteriosus.

Authors:  Niek Jozef Beijerink; Wilhelmina Bergmann; Viktor Szatmári
Journal:  J Vet Intern Med       Date:  2018-03-10       Impact factor: 3.333

7.  Percutaneous closure of a combined ventricular septal defect and paravalvular regurgitation after transcatheter aortic valve implantation: case report.

Authors:  Nynke H M Kooistra; Gregor J Krings; Pieter R Stella; Michiel Voskuil
Journal:  Eur Heart J Case Rep       Date:  2018-02-21

8.  Assessment of Device Neoendothelialization With Cardiac Computed Tomography Angiography After Transcatheter Closure of Atrial Septal Defect.

Authors:  Ah Young Kim; Wongi Woo; Beom Jin Lim; Jo Won Jung; Jae Young Choi; Young Jin Kim
Journal:  Circ Cardiovasc Imaging       Date:  2022-07-19       Impact factor: 8.589

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.